SOAT1 and breast carcinoma: We selected three breast cancer cell lines, and three molecularly-targeted drugs: (a) Ruxolitinib (RUX; pan-JAK inhibitor): Janus kinases (JAKs) are a family of enzymes involved in JAK/STAT pathway, and ruxolitinib is a pan inhibitor with more selectivity toward JAK1 and 2 (22).